- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03593291
LMWH-VTE Prophylaxis for Survivors of Acute Ischemic Stroke- Assessment of Standard Dosing Regimen
Anti Xa Blood Levels at Survivors of Acute Ischemic Stroke- Receiving LMWH-VTE Prophylaxis
The anti-factor Xa (anti-Xa) assay is a functional assay that facilitates the measurement of antithrombin (AT)-catalyzed inhibition of factor Xa by unfractionated heparin (UFH) and direct inhibition of factor Xa by low-molecular-weight heparin (LMWH). As a result, Anti-factor Xa level reflect the in situ pharmacological activity of LMWH. 0.2 to 0.5 units/ml has been considered to be the desired level for prevention of VTE. Although this method was available since the 1970s, their cost was viewed to prohibit their broad use until recently.
Previous studies determined the safety and effectiveness of fixed dose prophylactic regiments via clinical outcomes. This strategy has several shortcomings.
The current study was there for devised to examine in vivo activity of LMWH in patients receiving a fixed dose prophylactic regimen, in order to assess the effectiveness of this method.
Study Overview
Detailed Description
The anti-factor Xa (anti-Xa) assay is a functional assay that facilitates the measurement of antithrombin (AT)-catalyzed inhibition of factor Xa by unfractionated heparin (UFH) and direct inhibition of factor Xa by low-molecular-weight heparin (LMWH). As a result, Anti-factor Xa level reflect the in situ pharmacological activity of LMWH. 0.2 to 0.5 units/ml has been considered to be the desired level for prevention of VTE. Although this method was available since the 1970s, their cost was viewed to prohibit their broad use until recently.
Previous studies determined the safety and effectiveness of fixed dose prophylactic regiments via clinical outcomes. This strategy has several shortcomings.
The current study was there for devised to examine in vivo activity of LMWH in patients receiving a fixed dose prophylactic regimen, in order to assess the effectiveness of this method.
Purpose To perform an exploratory prospective analysis of longitudinal data sets to assess anti-factor Xa levels in a cohort of patients recovering from acute ischemic stroke and receiving prophylactic-dose LMWH for VTE prevention.
Primary Outcome Measures:
- assess anti-factor Xa levels
- adverse events related to thrombosis
- adverse event related to hemorrhage
Secondary Outcome Measures:
Patient demographic data Patient anthropometric data Adverse events/weekly (falls, infections, VTE, stress ulcer…) Eligibility
Ages Eligible for Study: 40 Years to 80 Years (Adult, Senior) Gender Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Patients hospitalized for rehabilitation following acute ischemic stroke
Methods:
Clinical decision to administer LMWH prophylactic treatment will be made in line with standard clinical practice and in accordance to the criteria described above.
Search for patients diagnosed with sub-acute stroke and receiving LMWH treatment will be performed on the digital database of the Loewenstien rehabilitation hospital Rannana, Israel.
Patients receiving LMWH prophylaxis with fixed dose regimen will be recruited flowing signing of consent form.
Flowing at least 7 consecutive days of treatment blood sample will be drown 3-4 hours post LMWH administration and sent for The anti-factor Xa (anti-Xa) assay. In the event of high or low results the Hematological consult will be contacted for decision about dose adjustment or other intervention/investigation.
All data will be drawn from patient's electronic/hardcopy files. patient characteristics (age, gender, , past medical history), Stroke characteristics (type, location, NIHSS), days from stroke onset to rehabilitation admission, along with each patient's length of stay, neurological impairments, and Rehabilitation outcomes. Trained research associates, who are familiar with the process of chart review, will extract the information from the charts using the form provided.
Statistical analysis: multi variant combative analysis of outcome measures will be carried out to compare study and control groups.
Estimated Enrollment: 100 patients
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Motti Ratmansky, MD
- Phone Number: +97297709102
- Email: mottir@clalit.org.il
Study Contact Backup
- Name: Deborah Rubin-Asher, MD
- Phone Number: +97297709164
- Email: dasher@clalit.org.il
Study Locations
-
-
-
Ra'anana, Israel
- Loewenstein Hospital
-
Contact:
- Moti Ratmansky, MD
- Phone Number: 97297709907
- Email: MottiR@clalit.org.il
-
Contact:
- Deborah Asher, MD
- Phone Number: 97297709164
- Email: dasher@clalit.org.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Acute Ischemic stroke per imaging study
- Clinical decision to administer VTE prophylaxis. (i.e.patients in whom a diagnosis of hemorrhagic stroke has been excluded, the risk of bleeding (hemorrhagic transformation of stroke or bleeding into another site) is assessed to be low, and who have one or more of the following: • major restriction of mobility • previous history of VTE • dehydration or comorbidities (such as malignant disease).Age: 55-80 years)
Exclusion criteria:
- Obese (>150 KG)
- Suffer from renal insufficiency (ccl<30)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-Xa level
Time Frame: 3-4 hours post LMWH administration
|
Flowing at least 7 consecutive days of treatment blood sample will be drown 3-4 hours post LMWH administration and sent for The anti-factor Xa (anti-Xa) assay.
|
3-4 hours post LMWH administration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Motti Ratmansky, MD, Loewenstein Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Ischemic Stroke
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Heparin, Low-Molecular-Weight
- Dalteparin
Other Study ID Numbers
- 0022-17-LOE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Anti Xa
-
Toltec Pharmaceuticals, LLCCompleted
-
Steward St. Elizabeth's Medical Center of Boston...CompletedAtrial FibrillationUnited States
-
Xuanwu Hospital, BeijingPeking University First HospitalRecruitingVenous ThromboembolismChina
-
University Hospital, GrenobleCelgene CorporationUnknownVenous Thromboembolism | MyelomaFrance
-
Seoul National University HospitalRecruitingAtrial Fibrillation | Anticoagulant-induced BleedingKorea, Republic of
-
Nantes University HospitalUnknownAtrial Fibrillation | Venous Thromboembolism | Anticoagulation
-
Abbott Medical DevicesTerminatedAtrial FibrillationUnited States
-
Cardica, IncTerminatedCoronary Artery DiseaseGermany
-
Assistance Publique - Hôpitaux de ParisAction Research Group; Bristol-Meyers Squibb & PfizerCompletedSymptomatic Aortic Stenosis | Eligible for Transcatheter Aortic Valve ReplacementFrance, Germany, Italy, Spain
-
Mohamed Sayed Mohamed AbbasCompletedAnti-Xa Assay in Pulmonary Embolism